Methods and compositions to treat myocardial conditions

Abstract

Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structural reinforcing agents such as those agents containing aloe-derived pectin. In other embodiments, the structural reinforcing agent may be accompanied by other therapeutic agents. These agents may include, but are not, limited to pro-fibroblastic and angiogenic agents.

1 . A method comprising identifying an infarct region within the ventricle of a subject; and
 delivering near or in the infarct region material comprising aloe-derived pectin.   
   
   
       2 . A method comprising identifying an infarct region within the ventricle of a subject; and
 delivering to the infarct region material comprising aloe-derived pectin.   
   
   
       3 . The method of  claim 1  wherein delivering aloe-derived pectin prevents thinning of the ventricle. 
   
   
       4 . The method of  claim 1  wherein delivery of the aloe-derived pectin occurs within 2 weeks of a myocardial infarction (MI). 
   
   
       5 . The method of  claim 1  wherein delivery of the aloe-derived pectin occurs within 5, 10, 15, or 20 weeks of a myocardial infarction (MI). 
   
   
       6 . The method of  claim 1  wherein the aloe-derived pectin material further comprises at least one of cells, proteins, peptides, growth factors or microparticles containing at least one of cells, proteins, peptides, or growth factors or nanoparticles containing at least one of cells, proteins, peptides or growth factors. 
   
   
       7 . The method of  claim 6  wherein the aloe-derived pectin material comprises cells and proteins, cells and growth factors, or proteins and growth factors. 
   
   
       8 . The method of  claim 1  wherein said subject with the MI displays at least 20 percent ventricular damage. 
   
   
       9 . The method of  claim 1  wherein the aloe-derived pectin displays a pseudoplastic characteristic. 
   
   
       10 . The method of  claim 1  wherein delivering aloe-derived pectin comprises: delivering the aloe-derived pectin material to the infarct region in a liquid phase and once delivered the aloe-derived pectin material is capable of transitioning to a solid phase in the presence of an endogenous material. 
   
   
       11 . The method of  claim 1  further comprising delivering at least one matrix metalloproteinase inhibitor (MMPIs) to the ventricle. 
   
   
       12 . The method of  claim 1  wherein delivering the aloe-derived pectin comprises introducing the aloe-derived pectin to the ventricle through a procedure. 
   
   
       13 . The method of  claim 12  wherein the procedure to the ventricle region is selected from at least one of minimally invasive such as sub-xiphoid, percutaneous, or surgical approach such as open-chest procedure in conjunction with Coronary Bypass Graft (CABG). 
   
   
       14 . The method of  claim 13  wherein the percutaneous introduction of the aloe-derived pectin into the ventricle comprises at least one of the following modes consisting of intracoronary infusion, intraventricular catheter, intravenous pressure perfusion, transvascular needle catheter, and retrograde venous perfusion. 
   
   
       15 . The method of  claim 1  wherein delivering the aloe-derived pectin comprises delivering a composition suspended in a solution. 
   
   
       16 . The method of  claim 1  wherein delivering aloe-derived pectin near the infarct region is capable of increasing the compliance of the ventricle. 
   
   
       17 . A kit comprising a delivery lumen; agents delivered from the delivery lumen; and at least one agent comprising a structural reinforcing agent wherein said structural reinforcing agent is capable of forming a matrix product within a ventricle wherein the structural re-inforcing agent comprises a material comprising aloe-derived pectin. 
   
   
       18 . The kit of  claim 17  further comprising forming a matrix product within or near an infarct region of a ventricle. 
   
   
       19 . The kit of  17  further comprising a delivery device. 
   
   
       20 . The kit of  17  wherein the structural reinforcing agent comprises a material in a liquid phase and once delivered the material is capable of transitioning to a solid phase in the presence of an endogenous material in or near an infarct region. 
   
   
       21 . A kit comprising a delivery lumen and agents comprising aloe-derived pectin, wherein the agents are capable of increasing the compliance of a ventricle. 
   
   
       22 . The kit of  claim 21  further comprising a delivery device. 
   
   
       23 . A method comprising delivering a liquid phase of a structural reinforcing agent to a ventricle wherein the structural reinforcing agent is capable of transitioning to a solid when an environmental temperature is approximately a body temperature of a mammalian subject and wherein the structural reinforcing agent comprises a material comprising aloe-derived pectin. 
   
   
       24 . The method of  claim 23  wherein delivering a liquid phase of a structural reinforcing agent to a ventricle comprises delivering a liquid phase of a structural reinforcing agent to or near an infarct region of a ventricle. 
   
   
       25 . A method comprising delivering a first material and a second different material to a ventricle wherein a first material and a second different material are components of a final product and wherein the first or second material comprises aloe-derived pectin. 
   
   
       26 . The method of  claim 25  wherein the final product prevents thinning of the ventricle. 
   
   
       27 . A kit comprising at least two delivery lumen; agents delivered from each delivery lumen; and a first material and a second different material wherein the first material and the second different material are components of a final product and are capable of forming the final product within a ventricle and wherein the first or second material comprises aloe-derived pectin. 
   
   
       28 . The kit of  claim 27  wherein the first material and the second material are housed in separate lumen. 
   
   
       29 . The kit of  claim 27  wherein a final product is formed within or near an infarct region of a ventricle from the first material and the second material. 
   
   
       30 . The kit of  claim 27  further comprising a delivery device. 
   
   
       31 . The kit of  claim 30  wherein the delivery device comprises a dual chamber delivery device comprising separate chambers for the first material and the second different material.